DEFC14A: Deep Track Launches Proxy Fight at Dynavax Over Capital Allocation and Board Composition

Deep Track Biotechnology Master Fund is soliciting proxies to elect four director nominees to the Dynavax Technologies Corporation board, citing concerns over the company's capital allocation strategy and board entrenchment.

Summary

• Deep Track Biotechnology Master Fund, owning approximately 14.3% of Dynavax, is seeking to elect four new independent directors to the company's board at the 2025 Annual Meeting.
• Deep Track believes the current board is pursuing a misguided acquisition strategy instead of focusing on maximizing the value of Heplisav.
• The proxy statement outlines a history of engagement between Deep Track and Dynavax, including concerns raised about capital allocation, the stock repurchase program, and board composition.
• Deep Track is proposing the election of Brett A. Erkman, Jeffrey S. Farrow, Michael Mullette, and Donald J. Santel as Class I directors.
• Deep Track is also recommending stockholders vote for the advisory vote on executive compensation, the ratification of Ernst & Young LLP as the independent registered public accounting firm, the approval of the Declassification Plan, and the approval of the Bylaw Proposal.
• The 2025 Annual Meeting is scheduled for June 11, 2025.
• Deep Track is seeking reimbursement from the Company of all costs incurred by the Deep Track Parties in connection with expenses the Deep Track Parties incur in connection with the solicitation of proxies for the election of the Deep Track Nominees to the Board at the 2025 Annual Meeting.

Sentiment

Score: 4

Explanation: The document expresses dissatisfaction with the company's current strategy and performance, indicating a negative sentiment. However, it also expresses confidence in the management team and a desire to work constructively with the board, suggesting a more nuanced view.

Positives

• Deep Track's nominees bring financial, healthcare-related, and corporate governance experience.
• The proposed board changes could lead to a more shareholder-focused strategy.
• Deep Track's involvement may increase accountability and drive improved performance.
• The Declassification Plan, while phased in, is a step towards greater board accountability.

Negatives

• The Deep Track Nominees, if elected, will constitute a minority on the Board and, therefore, they may be unable to implement any actions that may be necessary to enhance stockholder value.
• The Company has made only perfunctory moves to appear shareholder-friendly, such as announcing a $200 million share buyback something Deep Track Capital (and others) had long implored the Company to do, but which only occurred after Deep Track Capital publicly surfaced and declassifying a staggered board after our criticism, but only over the course of years, with its full effect not taking place until 2028.

Risks

• The proxy fight could be costly and disruptive to Dynavax.
• There is no guarantee that Deep Track's nominees will be elected.
• Even if elected, the Deep Track nominees may not be able to implement their desired changes.
• The Company has a Stockholder Rights Plan, effectively limiting holders to 15% ownership, and disclosed that the adoption of such rights plan was in response to the recent accumulations of stock by Deep Track Capital.

Future Outlook

Deep Track aims to work with the board to maximize stockholder value, but acknowledges that as a minority, they may face challenges in implementing necessary actions.

Management Comments

• Deep Track believes that the Companys empire-building strategy of seeking acquisitions that lack strategic rationale instead of focusing on leveraging the potential of its major asset, Heplisav, is putting Stockholders investments at risk.
• Deep Track believes change is clearly and urgently required at the Company.
• Deep Track believes that the Company has lost credibility among the investment community, as evidenced by a stock price that underperformed two prominent biotech indices over the one and three-year periods prior to the filing of our beneficial ownership report disclosing a 13.6% ownership interest in the Company, and the relatively small number of specialist healthcare investors in the Company.

Industry Context

This proxy fight reflects a growing trend of activist investors challenging biotech companies to improve capital allocation and strategic focus.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards.
• However, it implies that Dynavax's stock price underperformance relative to biotech indices suggests a need for improvement.
• The document references the Company's convertible debt issuance, but does not compare it to industry standards.

Management Changes

Corporate Governance

Legal Proceedings

• Deep Track Capital sent a Section 220 demand letter to the Company, asking for the Companys stockholder lists and related information.

Stakeholder Impact

• Shareholders: The outcome of the proxy fight will directly impact the company's strategic direction and potentially its stock price.
• Employees: Uncertainty surrounding the company's future strategy could affect employee morale.
• Customers: A change in strategic focus could impact the development and commercialization of Dynavax's products.
• Creditors: The company's financial strategy and capital allocation decisions could impact its creditworthiness.

Next Steps

• Stockholders are urged to vote using the WHITE proxy card.
• The 2025 Annual Meeting will be held on June 11, 2025.
• Deep Track intends to seek reimbursement from the Company of all costs incurred by the Deep Track Parties in connection with expenses the Deep Track Parties incur in connection with the solicitation of proxies for the election of the Deep Track Nominees to the Board at the 2025 Annual Meeting.

Key Dates

Keywords

proxy solicitation, board of directors, Dynavax, Deep Track Capital, Heplisav, capital allocation, corporate governance, shareholder value, director nominees, annual meeting